hydralazine has been researched along with Vasculitis in 13 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydralazine is an antihypertensive medication that has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV)." | 7.88 | Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. ( Kumar, B; Lenert, P; Strouse, J; Suneja, M; Swee, M, 2018) |
| "We report a rare case of Hydralazine-induced ANCA associated glomerulonephritis with alveolar hemorrhage in the setting of acute Clostridium Difficile Infection." | 7.83 | Hydralazine-Induced ANCA Vasculitis in the Setting of Acute Clostridium Difficile Infection. ( Cucu, DF; El Meligy, A; Rasla, S, 2016) |
| "We have previously found that T lymphocytes are essential for development of angiotensin II-induced hypertension; however, the mechanisms responsible for T-cell activation in hypertension remain undefined." | 7.76 | Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. ( Gordon, FJ; Guzik, TJ; Harrison, DG; Lob, HE; Marvar, PJ; McCann, LA; Thabet, SR; Weyand, C, 2010) |
| "Renal cell carcinoma and hydralazine drug therapy has each been reported as rare associations with pauci-immune renal vasculitis." | 7.72 | P-ANCA positive renal vasculitis in association with renal cell carcinoma and prolonged hydralazine therapy. ( Jeffrey, RF; Leeds, J; Norris, JH, 2003) |
| " The present study was aimed to investigate distribution of anti-lactoferrin antibodies in systemic lupus erythematosus, the hydralazine-induced SLE-like syndrome, and in rheumatoid arthritis compared to RA complicated with vasculitis." | 7.69 | Occurrence of anti-lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine-induced lupus, and rheumatoid arthritis. ( Hultquist, R; Nässberger, L; Sturfelt, G, 1994) |
| " Hoarseness developed in a 60-year-old man that was secondary to ulcerated lesions, which involved the epiglottis and aryteno-epiglottic folds, with serologic evidence of SLE after he had been treated with hydralazine for six months." | 7.67 | Hydralazine hoarseness. A new appearance of drug-induced systemic lupus erythematosus. ( Forouhar, FA; Weiser, GA; White, WB, 1984) |
| "Hydralazine is an antihypertensive medication that has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV)." | 3.88 | Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. ( Kumar, B; Lenert, P; Strouse, J; Suneja, M; Swee, M, 2018) |
| "Hydralazine-induced small vessel vasculitis is a rare entity with a limited number of cases reported in the dermatologic literature." | 3.85 | Hydralazine-associated cutaneous casculitis presenting with aerodigestive tract involvement. ( Harp, J; Horowitz, J; Levin, LE; Magro, C, 2017) |
| "We report a rare case of Hydralazine-induced ANCA associated glomerulonephritis with alveolar hemorrhage in the setting of acute Clostridium Difficile Infection." | 3.83 | Hydralazine-Induced ANCA Vasculitis in the Setting of Acute Clostridium Difficile Infection. ( Cucu, DF; El Meligy, A; Rasla, S, 2016) |
| "We have previously found that T lymphocytes are essential for development of angiotensin II-induced hypertension; however, the mechanisms responsible for T-cell activation in hypertension remain undefined." | 3.76 | Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. ( Gordon, FJ; Guzik, TJ; Harrison, DG; Lob, HE; Marvar, PJ; McCann, LA; Thabet, SR; Weyand, C, 2010) |
| "Renal cell carcinoma and hydralazine drug therapy has each been reported as rare associations with pauci-immune renal vasculitis." | 3.72 | P-ANCA positive renal vasculitis in association with renal cell carcinoma and prolonged hydralazine therapy. ( Jeffrey, RF; Leeds, J; Norris, JH, 2003) |
| "In this study, we determined the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previously implicated in APV among 30 patients with vasculitis and the highest titers of anti-MPO antibodies newly detected in our laboratory between 1994 and 1998." | 3.70 | Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. ( Choi, HK; Merkel, PA; Niles, JL; Walker, AM, 2000) |
| " The present study was aimed to investigate distribution of anti-lactoferrin antibodies in systemic lupus erythematosus, the hydralazine-induced SLE-like syndrome, and in rheumatoid arthritis compared to RA complicated with vasculitis." | 3.69 | Occurrence of anti-lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine-induced lupus, and rheumatoid arthritis. ( Hultquist, R; Nässberger, L; Sturfelt, G, 1994) |
| " Hoarseness developed in a 60-year-old man that was secondary to ulcerated lesions, which involved the epiglottis and aryteno-epiglottic folds, with serologic evidence of SLE after he had been treated with hydralazine for six months." | 3.67 | Hydralazine hoarseness. A new appearance of drug-induced systemic lupus erythematosus. ( Forouhar, FA; Weiser, GA; White, WB, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Levin, LE | 1 |
| Magro, C | 1 |
| Horowitz, J | 1 |
| Harp, J | 1 |
| Kumar, B | 1 |
| Strouse, J | 1 |
| Swee, M | 1 |
| Lenert, P | 1 |
| Suneja, M | 1 |
| Rasla, S | 1 |
| El Meligy, A | 1 |
| Cucu, DF | 1 |
| Marvar, PJ | 1 |
| Thabet, SR | 1 |
| Guzik, TJ | 1 |
| Lob, HE | 1 |
| McCann, LA | 1 |
| Weyand, C | 1 |
| Gordon, FJ | 1 |
| Harrison, DG | 1 |
| Norris, JH | 1 |
| Leeds, J | 1 |
| Jeffrey, RF | 1 |
| Weiser, GA | 1 |
| Forouhar, FA | 1 |
| White, WB | 1 |
| Macleod, WN | 1 |
| Nässberger, L | 1 |
| Hultquist, R | 1 |
| Sturfelt, G | 1 |
| Cambridge, G | 1 |
| Wallace, H | 1 |
| Bernstein, RM | 1 |
| Leaker, B | 1 |
| Choi, HK | 1 |
| Merkel, PA | 1 |
| Walker, AM | 1 |
| Niles, JL | 1 |
| Martinez-Vea, A | 1 |
| Ferrer, I | 1 |
| Carcía, C | 1 |
| Mayayo, E | 1 |
| Oliver, JA | 1 |
| Richart, C | 1 |
| Stevens, MB | 1 |
| Doherty, M | 1 |
| Maddison, PJ | 1 |
| Grey, RH | 1 |
1 review available for hydralazine and Vasculitis
| Article | Year |
|---|---|
Connective tissue disease in the elderly.
Topics: Aged; Connective Tissue Diseases; Dermatomyositis; Female; Giant Cell Arteritis; Humans; Hydralazine | 1986 |
12 other studies available for hydralazine and Vasculitis
| Article | Year |
|---|---|
Hydralazine-associated cutaneous casculitis presenting with aerodigestive tract involvement.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents; Diagnosis, Differential; Fema | 2017 |
Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis.
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents; Female; Humans; Hydralazine; | 2018 |
Hydralazine-Induced ANCA Vasculitis in the Setting of Acute Clostridium Difficile Infection.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents; Clos | 2016 |
Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension.
Topics: Administration, Oral; Adoptive Transfer; Angiotensin II; Animals; Antihypertensive Agents; Blood Pre | 2010 |
P-ANCA positive renal vasculitis in association with renal cell carcinoma and prolonged hydralazine therapy.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents; Carcinoma, Renal Cell; Humans; Hydr | 2003 |
Hydralazine hoarseness. A new appearance of drug-induced systemic lupus erythematosus.
Topics: Epiglottis; Hoarseness; Humans; Hydralazine; Laryngeal Diseases; Lupus Erythematosus, Systemic; Male | 1984 |
Anaemia in the hydrallazine-induced Lupus syndrome.
Topics: Aged; Anemia; Humans; Hydralazine; Lupus Erythematosus, Systemic; Male; Syndrome; Vasculitis | 1983 |
Occurrence of anti-lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine-induced lupus, and rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Female; Humans; H | 1994 |
Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis.
Topics: Adolescent; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibody Specificity; Autoantibodie | 1994 |
Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antibodies; Antibodies, Antineutrophil Cyto | 2000 |
Systemic vasculitis resembling periarteritis nodosa in the lupus-like syndrome induced by hydralazine.
Topics: Adult; Humans; Hydralazine; Lupus Erythematosus, Systemic; Male; Polyarteritis Nodosa; Vasculitis | 1987 |
Hydralazine induced lupus syndrome with eye disease.
Topics: Female; Humans; Hydralazine; Hypertension; Lupus Erythematosus, Systemic; Middle Aged; Retinitis; Sy | 1985 |